Although the initial characterization of the cellular and molecular effects of NT157 was performed in KRAS-mutated lung cancer cells, key findings of the present study were also observed in EGFR-mutated lung cells, including a dose-dependent reduction in cell viability and clonogenicity, reduction in AXL-mediated signaling, JNK activation and potentiating effects in combination therapy with gefitinib (Supplementary Fig. 6). Here, KRAS is linked to lung cancer.